Friday, 11 June 2010

How the Wrong Genes are Repressed in Stem Cells

How the Wrong Genes are Repressed in Stem Cells
Friday, 11 June 2010

The mechanism by which 'polycomb' proteins critical for embryonic stem cell function and fate are targeted to DNA has been identified by UCL scientists.



PRC2 is brought to its target genes though binding to short RNA transcribed by RNA polymerase II. PRC2 can then methylate histone H3 (which the DNA is wrapped around), blocking full transcription of developmental regulator genes that would otherwise act to alter the identity of the cell.


The discovery, which has implications for the fields of stem cell and tissue engineering, is detailed in research published today in the journal Molecular Cell.

A key feature of stem cells is the suppression of genes that when later switched on lead to the differentiation of the cells into specific mature cell types, such as neurons or immune cells. Polycomb proteins, first discovered in fruit flies, are known to play a critical role in the suppression of these developmental genes. PRC2 (polycomb repressive complex-2) is present in all multicellular organisms and has been shown to be important in stem cell differentiation and early embryonic development.

The study authors found that PRC2 is brought to its target genes though binding to a new class of short RNAs transcribed by RNA polymerase II. PRC2 can then methylate chromatin, preventing the activation of developmental regulator genes that would otherwise act to alter the identity of the cell.

Senior author Dr Richard Jenner, UCL Infection & Immunity, said:

"We knew that different sets of genes are turned on in different cells and that polycomb proteins prevent the wrong genes from being turned on, for example polycomb prevents the activation of neuronal genes in immune cells. However, although polycomb proteins repress genes, they are actually in a poised state – some sort of gene activity seemed to be occurring.”

"We wanted to find out what this activity was and our identification of these short RNAs explains this unusual gene state. Discovering that polycomb also binds to these RNAs shows how polycomb might be recruited to genes, which are then repressed to maintain the identities of different cell types. This has been a key question in the field for some time and has important implications for how we might be able to control cell fate in tissue engineering".

Reference:
Short RNAs Are Transcribed from Repressed Polycomb Target Genes and Interact with Polycomb Repressive Complex-2
Aditi Kanhere, Keijo Viiri, Carla C. Araújo, Jane Rasaiyaah, Russell D. Bouwman, Warren A. Whyte, C. Filipe Pereira, Emily Brookes, Kimberly Walker, George W. Bell, Ana Pombo, Amanda G. Fisher, Richard A. Young, Richard G. Jenner
Molecular Cell, Volume 38, Issue 5, 675-688, 11 June, 10.1016/j.molcel.2010.03.019
.........


ZenMaster

For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Thursday, 10 June 2010

Stem Cells for First Time Used to Create Abnormal Heart Cells

Will be used for study of cardiomyopathy
Thursday, 10 June 2010

Researchers at Mount Sinai School of Medicine have for the first time differentiated human stem cells to become heart cells with cardiomyopathy, a condition in which the heart muscle cells are abnormal. The discovery will allow scientists to learn how those heart cells become diseased and from there, they can begin developing drug therapies to stop the disease from occurring or progressing. The study is published in the June 9th issue of Nature.

The Mount Sinai team used skin cells from two patients with a genetic disorder known by the acronym LEOPARD syndrome. Hypertrophic cardiomyopathy, or thickening of the heart muscle, is experienced by 80 percent of patients with LEOPARD syndrome and is the most life-threatening aspect of the disorder. The Mount Sinai team took patient skin cells and reprogrammed them to become pluripotent stem cells. Such cells can then develop into almost any type of cell in the human body. The researchers then created heart cells that had characteristics of hypertrophic cardiomyopathy.

"We knew there was potential in using pluripotent stem cells from people with genetic disorders to develop diseases in vitro, but our study is the first to successfully create abnormal heart cells," said the Principal Investigator of the study Ihor R. Lemischka, PhD, Professor, Gene and Cell Medicine, Developmental and Regenerative Biology, Mount Sinai School of Medicine.

"Now that we have developed these cells, we can study why they become enlarged and develop treatments to prevent them from overgrowing."

Scientists know that genetic disorders occur because of a mutation in a protein signalling pathway called the RAS pathway, but they have been unable to determine precisely how this results in disease-associated problems like hypertrophic cardiomyopathy. The authors of the Nature study concluded that induced pluripotent stem cell-derived heart cells provide the required characteristics to precisely determine the pathology behind these disorders, and a foundation for studying treatment interventions.

"This discovery has broad-reaching implications for genetic diseases like LEOPARD syndrome and Noonan's syndrome," continued Dr. Lemischka.

"We look forward to further studying these cells as a potential therapeutic target."

Reference:
Patient-specific induced pluripotent stem-cell-derived models of LEOPARD syndrome
Xonia Carvajal-Vergara, Ana Sevilla, Sunita L. D’Souza, Yen-Sin Ang, Christoph Schaniel, Dung-Fang Lee, Lei Yang, Aaron D. Kaplan, Eric D. Adler, Roye Rozov, YongChao Ge, Ninette Cohen, Lisa J. Edelmann, Betty Chang, Avinash Waghray, Jie Su, Sherly Pardo, Klaske D. Lichtenbelt, Marco Tartaglia, Bruce D. Gelb & Ihor R. Lemischka
Nature 465, 808–812, 10 June 2010), doi:10.1038/nature09005
.........


ZenMaster


For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/

Wednesday, 9 June 2010

New Type of Human Stem Cell May be More Easy to Manipulate

Changing growth factors produce cells that should be more useful for research, future therapies
Wednesday, 09 June 2010

Researchers from the Massachusetts General Hospital Center for Regenerative Medicine (MGH-CRM) and the Harvard Stem Cell Institute have a developed a new type of human pluripotent stem cell that can be manipulated more readily than currently available stem cells. As described in the June 4 Cell Stem Cell, these new cells could be used to create better cellular models of disease processes and eventually may permit repair of disease-associated gene mutations.

"It has been fairly easy to manipulate stem cells from mice, but this has not been the case for traditional human stem cells," explains Niels Geijsen, PhD, of the MGH-CRM, who led the study.

"We had previously found that the growth factors in which mouse stem cells are derived define what those cells can do, and now we've applied those findings to human stem cells."

The first mammalian embryonic stem cells (ESCs) were derived from mice and have proven very useful for studying gene function and the impact of changes to individual genes. However, techniques used in these studies to introduce a different version of a single gene or inactivate a particular gene were ineffective in human ESCs. In addition, human ESCs proliferate much more slowly than do cells derived from mice and grow in flat, two-dimensional colonies, while mouse ESCs form tight, three-dimensional colonies. It has been extremely difficult to propagate human ESCs from a single cell, which prevents the creation of genetically manipulated human embryonic stem cell lines.

In previous work, Geijsen and his colleagues demonstrated that the growth factor conditions under which stem cells are maintained in culture play an important role in defining the cells' functional properties. Since the growth factors appeared to make such a difference, the researchers tried to make a more useful human pluripotent cell using a new approach. They derived human induced pluripotent stem cells (iPSCs) – which are created by reprogramming adult cells and have many of the characteristics of human ESCs, including resistance to manipulation – in cultures containing the growth factor LIF, which is used in the creation of mouse ESCs.

The resulting cells visibly resembled mouse ESCs and proved amenable to a standard gene manipulation technique that exchanges matching sequences of DNA, allowing the targeted deactivation or correction of a specific gene. The ability to manipulate these new cells depended on both the continued presence of LIF and expression of the five genes that are used in reprogramming adult cells into iPSCs. If any of those factors was removed, these hLR5- (for human LIF and five reprogramming factors) iPSCs reverted to standard iPSCs.

"Genetic changes introduced into hLR5-iPSCs would be retained when they are converted back to iPSCs, which we then can use to generate cell lines for future research, drug development and someday stem-cell based gene-correction therapies," says Geijsen. He is an assistant professor of Medicine at Harvard Medical School and a principal faculty member of the Harvard Stem Cell Institute.

Reference:
A Murine ESC-like State Facilitates Transgenesis and Homologous Recombination in Human Pluripotent Stem Cells
Christa Buecker, Hsu-Hsin Chen, Jose Maria Polo, Laurence Daheron, Lei Bu, Tahsin Stefan Barakat, Patricia Okwieka, Andrew Porter, Joost Gribnau, Konrad Hochedlinger, Niels Geijsen
Cell Stem Cell, Volume 6, Issue 6, 535-546, 4 June 2010, 10.1016/j.stem.2010.05.003
.........


ZenMaster

For more on stem cells and cloning, go to CellNEWS at
http://cellnews-blog.blogspot.com/